

ARA290 and the ventilatory response to hypoxia and pain responses in healthy volunteers.

No registrations found.

| | |
|------------------------------|------------------|
| Ethical review | Positive opinion |
| Status | Recruiting |
| Health condition type | - |
| Study type | Interventional |

Summary

ID

NL-OMON23515

Source

Nationaal Trial Register

Brief title

ARA study

Health condition

Hypoxia; Hypoxic Pulmonary Vasoconstriction; Hypoxic Ventilatory Response.

Sponsors and support

Primary sponsor: Leiden University Medical Center (LUMC)

Source(s) of monetary or material Support: Leiden University Medical Center (LUMC)

Intervention

Outcome measures

Primary outcome

1. Hypoxic Ventilatory Response (HVR);

2. Pulmonary Artery Pressure (PAP).

Secondary outcome

1. Systolic and diastolic cardiac functions;
2. Vital and ventilatory parameters;
3. Pain thresholds under hypoxia.

Study description

Background summary

Epo seems to have an effect on hypoxic sensing in the carotid body and might effect the sensing in the pulmonary vascular tree. We want to investigate if this is detectable and what an Epo analog like ARA290 does on the HVR and PAP.

Study objective

Are there effects of ARA290 and Epo on the ventilatory response to hypoxia. Are there effects of ARA290 and Epo on the gradient over the tricuspid valve during hypoxia and an estimation of the pulmonary artery pressure (PAP). Does ARA290 and/or Epo affect the pain responses?

Study design

T = 0 min arrival in the laboratory;

T = 15 min: insertion of IV and arterial line and drawing of a blood sample for Hemoglobin concentration measurement;

T = 30 min baseline measurements PAIN 10 min
ECHO 40 min RESPIRATION 40 min;

T = 120 min TREATMENT injection (ARA290, Epo, Placebo);

T = 150 min effect measurements PAIN 10 min
ECHO 40 min RESPIRATION 40 min;

T = 240 min End of Study.

Intervention

Healthy volunteers will each be seen for three sessions, with 2 weeks in between. Hypoxia will be induced using the computer driven Dynamic End-Tidal Forcing (DEF) Technique; end-tidal oxygen concentrations will be lowered to 5.8 kPa (about 45 mmHg) to reach an oxygen saturation of $80 \pm 2 \%$, whereas the PCO₂ level remains constant (end-tidal concentration is rest endtidal PCO₂ + 2-3 mmHg). The subjects will breathe in and out through a face mask with a pneumotachograph to measure ventilation on a breath-to-breath basis. The maximum pressure difference across the tricuspid valve (ΔP_{\max}) will be measured using Doppler echocardiography. An arterial line will provide information about the arterial blood gas and BP. Each time one substance, either NaCl 0,9%, Erythropoietin or ARA290, will be administered by intravenous injection. Cardiac output will be measured with the Vigileo monitor (Edwards Lifesciences) and by cross sectional echocardiography, using the diameter of the left ventricular outflow tract, with the image frozen in midsystole, to calculate the cross sectional area, assuming a circular profile. We will measure aortic blood velocity by continuous wave Doppler.

Contacts

Public

Dept. of Anesthesiology LUMC, P5-Q
R.R. Berendsen
Leiden 2300 RC
The Netherlands
+31 (0)71 5262301

Scientific

Dept. of Anesthesiology LUMC, P5-Q
R.R. Berendsen
Leiden 2300 RC
The Netherlands
+31 (0)71 5262301

Eligibility criteria

Inclusion criteria

The major inclusion criteria is that the subject has echo evidence of tricuspid regurgitation during systole, which is not clinically relevant but in fact can be demonstrated in most normal individuals.

Exclusion criteria

1. Obesity (BMI > 35);
2. Presence of medical disease (heart-, lung-, liver-, kidney-, neurologic disease; diabetes m.; pyrosis; diaphragmatic hernia);
3. Presence of psychiatric disease;
4. History of chronic alcohol or illicit drug use;
5. Allergy to study medications. For females we require the use of oral contraceptives.

Study design

Design

| | |
|---------------------|-------------------------------|
| Study type: | Interventional |
| Intervention model: | Crossover |
| Allocation: | Randomized controlled trial |
| Masking: | Single blinded (masking used) |
| Control: | Placebo |

Recruitment

| | |
|---------------------------|-------------|
| NL | |
| Recruitment status: | Recruiting |
| Start date (anticipated): | 01-10-2011 |
| Enrollment: | 16 |
| Type: | Anticipated |

Ethics review

| | |
|-------------------|------------------|
| Positive opinion | |
| Date: | 01-11-2011 |
| Application type: | First submission |

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

| Register | ID |
|----------|---------------------------------------------|
| NTR-new | NL2983 |
| NTR-old | NTR3131 |
| Other | METC LUMC / CCMO : p10144 / NL32314.058.10; |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |

Study results

Summary results

N/A